Previous close | 3.7300 |
Open | 3.6400 |
Bid | 3.4900 x 400 |
Ask | 3.5200 x 800 |
Day's range | 3.4400 - 3.7000 |
52-week range | 3.4400 - 8.5900 |
Volume | |
Avg. volume | 1,645,118 |
Market cap | 316.112M |
Beta (5Y monthly) | N/A |
PE ratio (TTM) | N/A |
EPS (TTM) | -1.3800 |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 20.00 |
Caribou Biosciences (CRBU) delivered earnings and revenue surprises of -17.95% and 19.03%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
-- Advancing CB-010 ANTLER Phase 1 trial in 2L LBCL; initial dose expansion data to be presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting -- -- Expanding into autoimmune diseases with IND cleared for CB-010 in lupus nephritis and extrarenal lupus; GALLOP Phase 1 clinical trial expected to initiate by YE 2024 -- -- Advancing four clinical-stage programs for hematologic malignancies and autoimmune diseases; multiple milestones ahead -- -- $345.9 million in cash, cash
BERKELEY, Calif., May 01, 2024 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced the company’s participation in the following investor conferences: 2024 RBC Capital Markets Global Healthcare Conference, New York, NYMay 14, 2024, fireside chat at 3:35 pm EDTWebcast BofA Securities 2024 Health Care Conference, Las Vegas, NVMay 15, 2024, corporate presentation at 3:40 pm PDTWebcast For more informa